Patents by Inventor Helen M. Blau

Helen M. Blau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200281959
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: January 6, 2020
    Publication date: September 10, 2020
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Publication number: 20200215094
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Publication number: 20200215095
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: January 6, 2020
    Publication date: July 9, 2020
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Publication number: 20200147103
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Application
    Filed: August 22, 2019
    Publication date: May 14, 2020
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Patent number: 10525075
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Grant
    Filed: February 22, 2014
    Date of Patent: January 7, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John Ramunas, Eduard Yakubov, Helen M. Blau, John Cooke
  • Patent number: 10449205
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: October 22, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Publication number: 20190167695
    Abstract: Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.
    Type: Application
    Filed: October 1, 2018
    Publication date: June 6, 2019
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Adelaida R. Palla, Andrew Tri Van Ho
  • Publication number: 20190048420
    Abstract: Shortened telomeres are diagnostic of genetic predisposition to cardiomyopathies, e.g. those related to defects in structural proteins expressed in cardiomyocytes.
    Type: Application
    Filed: February 22, 2017
    Publication date: February 14, 2019
    Inventors: Helen M. Blau, Chia Yu Alex Chang
  • Publication number: 20180200264
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Application
    Filed: March 9, 2018
    Publication date: July 19, 2018
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Publication number: 20180177799
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 28, 2018
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Patent number: 9918994
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: March 20, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Publication number: 20170252354
    Abstract: Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and/or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
    Type: Application
    Filed: April 26, 2017
    Publication date: September 7, 2017
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Andrew Tri Van Ho, Adelaida R. Palla
  • Publication number: 20150037295
    Abstract: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 5, 2015
    Inventors: Helen M. Blau, Kostandin Pajcini, Jason Pomerantz
  • Publication number: 20140370522
    Abstract: Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between sub-cellular compartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing ?-galactosidase fragments are provided. These ?-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided.
    Type: Application
    Filed: March 24, 2014
    Publication date: December 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Thomas S. Wehrman
  • Patent number: 8852579
    Abstract: Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: October 7, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Kostandin Pajcini, Jason Pomerantz
  • Publication number: 20140242155
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: February 22, 2014
    Publication date: August 28, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Publication number: 20140242154
    Abstract: Compounds and compositions for the transient expression of exogenous telomerase activity in a cell are provided. The compounds and compositions, which relate to a ribonucleic acid coding for a telomerase reverse transcriptase, are useful in the extension of telomeres in cells needing such treatment. Such cells include, for example, cells that contain shortened telomeres and cells from subjects that may benefit from telomere extension, for example subjects that suffer from, or are at risk of suffering from, age-related or other illnesses. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro or in vivo, and kits including the compounds or compositions and instructions for use.
    Type: Application
    Filed: February 22, 2014
    Publication date: August 28, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: John RAMUNAS, Eduard YAKUBOV, Helen M. BLAU, John COOKE
  • Publication number: 20140178913
    Abstract: Methods and compositions for detecting molecular interactions are provided. Aspects of the invention include the use of a reduced affinity enzyme complementation reporter system. Also provided are systems and kits for use in practicing embodiments of the methods.
    Type: Application
    Filed: September 24, 2013
    Publication date: June 26, 2014
    Inventors: Tom Wehrman, Helen M. Blau
  • Patent number: 8679832
    Abstract: Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between sub-cellular compartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing ?-galactosidase fragments are provided. These ?-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: March 25, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Thomas S. Wehrman
  • Patent number: 8586294
    Abstract: Methods and compositions are provided for detecting molecular translocations, particularly protein translocations within and between subcellular copartments, using at least two components that exhibit a localization-dependent difference in complementation activity. In particular, alpha-complementing ?-galactosidase fragments are provided. These ?-galactosidase reporter fragments display significantly enhanced enzymatic activity when one fragment is localized in a membrane. Methods for carrying out no-wash ELISA assays based on the reporter component system are also provided.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: November 19, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Helen M. Blau, Thomas S. Wehrman